Abstract
At present, diabetic kidney disease affects about 15-25 % of patients with type 1 diabetes (T1D) and 30-40 % of patients with type 2 diabetes (T2D). Several decades of extensive research have elucidated various pathways to be implicated in the development of diabetic kidney disease. These include metabolic factors beyond blood glucose (e.g. advanced glycation endproducts (AGEs)), haemodynamic factors (e.g. the renin angiotensin system (RAS)), intracellular signaling molecule proteins (e.g. protein kinase C (PKC)) and growth factors / cytokines (e.g. growth hormone (GH), insulin-like growth factors (IGFs), transforming growth factor ß (TGF-ß) and vascular endothelial growth factor (VEGF)). This review focusses on the role of three of these growth factors, i.e. GH, IGFs and VEGF. A brief discussion of each system is followed by description of its expression in the normal kidney. Then, for each system, in vitro, experimental and clinical evidence addressing the role of the system in diabetic kidney disease is presented. The interplay of each system to other potential pathways will also be adressed. Finally, well-known and potential therapeutic strategies targeting the GH / IGF and VEGF systems in a specific or indirect way will discussed.
Keywords: growth factor, cytokine, mouse, rat, diabetic nephropathy
Current Pharmaceutical Design
Title: The Involvement of Growth Hormone (GH), Insulin-Like Growth Factors (IGFs) and Vascular Endothelial Growth Factor (VEGF) in Diabetic Kidney Disease
Volume: 10 Issue: 27
Author(s): Allan Flyvbjerg, Dinah S. Khatir, Louise J.N. Jensen, Frederik Dagnæs-Hansen, Henning Gronbaek and Ruth Rasch
Affiliation:
Keywords: growth factor, cytokine, mouse, rat, diabetic nephropathy
Abstract: At present, diabetic kidney disease affects about 15-25 % of patients with type 1 diabetes (T1D) and 30-40 % of patients with type 2 diabetes (T2D). Several decades of extensive research have elucidated various pathways to be implicated in the development of diabetic kidney disease. These include metabolic factors beyond blood glucose (e.g. advanced glycation endproducts (AGEs)), haemodynamic factors (e.g. the renin angiotensin system (RAS)), intracellular signaling molecule proteins (e.g. protein kinase C (PKC)) and growth factors / cytokines (e.g. growth hormone (GH), insulin-like growth factors (IGFs), transforming growth factor ß (TGF-ß) and vascular endothelial growth factor (VEGF)). This review focusses on the role of three of these growth factors, i.e. GH, IGFs and VEGF. A brief discussion of each system is followed by description of its expression in the normal kidney. Then, for each system, in vitro, experimental and clinical evidence addressing the role of the system in diabetic kidney disease is presented. The interplay of each system to other potential pathways will also be adressed. Finally, well-known and potential therapeutic strategies targeting the GH / IGF and VEGF systems in a specific or indirect way will discussed.
Export Options
About this article
Cite this article as:
Flyvbjerg Allan, Khatir S. Dinah, Jensen J.N. Louise, Dagnæs-Hansen Frederik, Gronbaek Henning and Rasch Ruth, The Involvement of Growth Hormone (GH), Insulin-Like Growth Factors (IGFs) and Vascular Endothelial Growth Factor (VEGF) in Diabetic Kidney Disease, Current Pharmaceutical Design 2004; 10 (27) . https://dx.doi.org/10.2174/1381612043383106
DOI https://dx.doi.org/10.2174/1381612043383106 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Inflammatory Actions of the Heme Oxygenase-1 Pathway
Current Pharmaceutical Design Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Antiretroviral Drugs and The Kidney: Dosage Adjustment and Renal Tolerance
Current Pharmaceutical Design Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Therapeutic Targets for the Prevention of Type 1 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Effects of Cichorium Intybus Linn on Blood Glucose, Lipid Constituents and Selected Oxidative Stress Parameters in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets Faujasiopsis flexuosa (Lam.) C. Jeffrey (Asteraceae) – A Promising Traditionally used Endemic Medicinal Plant from Mauritius
Current Traditional Medicine Protective Effect of CCR5 Delta-32 Allele Against HIV-1 in Mexican Women
Current HIV Research Fenofibrate and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Phase 4 Studies in Heart Failure - What is Done and What is Needed?
Current Cardiology Reviews Common Drugs for Stabilization of Renal Function in the Progression of Diabetic Nephropathy and Their Relations with Hypertension Therapy
Current Diabetes Reviews Role of PI3K/AKT, cPLA2 and ERK1/2 Signaling Pathways in Insulin Regulation of Vascular Smooth Muscle Cells Proliferation
Cardiovascular & Hematological Disorders-Drug Targets Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design Wnt Signaling in Development, Disease and Translational Medicine
Current Drug Targets Synthesis and Biological Activity of 3-(substitutedphenyl)- 6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting Inflammation in Primary Cardiovascular Prevention
Current Pharmaceutical Design Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Natural AMPK Activators: An Alternative Approach for the Treatment and Management of Metabolic Syndrome
Current Medicinal Chemistry Role of Endothelin in Diabetic Retinopathy
Current Vascular Pharmacology A Systematic Review on Effect of Canagliflozin in Special Population
Current Diabetes Reviews